Literature DB >> 8035932

Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease.

M Contin1, R Riva, P Martinelli, P Cortelli, F Albani, A Baruzzi.   

Abstract

We prospectively evaluated over 4 years the intrasubject relationship between levodopa plasma concentration and the tapping effect after a standard oral levodopa test in 28 patients with mild-to-moderate idiopathic Parkinson's disease. The onset and duration of the tapping effect significantly shortened over years; response amplitude did not vary. Levodopa plasma kinetics remained unchanged. Pharmacodynamic modeling indicated a progressive decrease in the equilibration half-life between plasma drug concentration and effect, which correlated with the shorter motor response. No clear-cut change in maximum response (Emax) emerged, but levodopa concentration needed to yield 50% of maximum effect (EC50) significantly increased. These data indicate that the duration of motor response becomes a major determinant of drug efficacy over years. The modifications in levodopa effect-compartment equilibration half-life and EC50 further support the suggestion that alterations in cerebral levodopa kinetics have an important role in the development of response fluctuations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035932     DOI: 10.1212/wnl.44.7.1287

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

2.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

4.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.

Authors:  M Murata; H Mizusawa; H Yamanouchi; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.

Authors:  Robert L White; Meghan C Campbell; Dake Yang; William Shannon; Abraham Z Snyder; Joel S Perlmutter
Journal:  Mov Disord       Date:  2019-12-19       Impact factor: 10.338

Review 7.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

Review 8.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.

Authors:  N Simon; F Viallet; A Boulamery; A Eusebio; D Gayraud; J-P Azulay
Journal:  Eur J Clin Pharmacol       Date:  2016-03-03       Impact factor: 2.953

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.